Gwendalyn J. Randolph
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gwendalyn J. Randolph has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
Claudia Jakubzick
From the Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York
5 shared publicationsNico van Rooijen
Department of Molecular Cell Biology, Free University Medical Center, Amsterdam, The Netherlands
5 shared publicationsFrank Tacke
Department of Gene and Cell Medicine and Immunology Institute, Mount Sinai School of Medicine, New York, NY
4 shared publications- Emmanuel L. Gautier
Sorbonne Université, INSERM, Nutrition and obesities: systemic approach research group, Nutriomics, Paris, France
3 shared publications - Guzman Sanchez-Schmitz
Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, United States
3 shared publications Miriam Merad
Department of Gene and Cell Medicine and Institute for Immunology, Icahn Medical Institute, Mount Sinai School of Medicine , New York, NY 10029
3 shared publications
Latest Publications
- 1 May 2012
- Published by Elsevier in Immunobiology
- Vol. 217 (5) , 548-557
Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis
- 1 May 2012
- Published by Elsevier in Immunobiology
- Vol. 217 (5) , 548-557
Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis
- 10 June 2011
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 332 (6035) , 1268-1269
No Need to Coax Monocytes
Although inflammation has been thought to rely on recruitment of macrophages from the blood, tissue macrophages can proliferate for an inflammatory response.
- 10 June 2011
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 332 (6035) , 1268-1269
No Need to Coax Monocytes
Although inflammation has been thought to rely on recruitment of macrophages from the blood, tissue macrophages can proliferate for an inflammatory response.
- 1 June 2011
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 31 (6) , 1249-1250
Vascular Calcification
- 1 June 2011
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 31 (6) , 1249-1250
Vascular Calcification
- Open Access
- 2 May 2011
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 121 (5) , 2025-2036
Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe–/– mice during disease regression
Experimental models of atherosclerosis suggest that recruitment of monocytes into plaques drives the progression of this chronic inflammatory condition. Cholesterol-lowering therapy leads to plaque stabilization or regression in human atherosclerosis, characterized by reduced macrophage content, but the mechanisms that underlie this reduction are incompletely understood. Mice lacking the gene Apoe (Apoe–/– mice) have high levels of cholesterol and spontaneously develop atherosclerotic lesions. Here, we treated Apoe–/– mice with apoE-encoding adenoviral vectors that induce plaque regression, and investigated whether macrophage removal from plaques during this regression resulted from quantitative alterations in the ability of monocytes to either enter or exit plaques. Within 2 days after apoE complementation, plasma cholesterol was normalized to wild-type levels, and HDL levels were increased 4-fold. Oil red O staining and quantitative mass spectroscopy revealed that esterified cholesterol content was markedly reduced. Plaque macrophage content decreased gradually and was 72% lower than baseline 4 weeks after apoE complementation. Importantly, this reduction in macrophages did not involve migratory egress from plaques or CCR7, a mediator of leukocyte emigration. Instead, marked suppression of monocyte recruitment coupled with a stable rate of apoptosis accounted for loss of plaque macrophages. These data suggest that therapies to inhibit monocyte recruitment to plaques may constitute a more viable strategy to reduce plaque macrophage burden than attempts to promote migratory egress.
- 2 May 2011
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 121 (5) , 2025-2036
Open AccessSuppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe–/– mice during disease regression
Experimental models of atherosclerosis suggest that recruitment of monocytes into plaques drives the progression of this chronic inflammatory condition. Cholesterol-lowering therapy leads to plaque stabilization or regression in human atherosclerosis, characterized by reduced macrophage content, but the mechanisms that underlie this reduction are incompletely understood. Mice lacking the gene Apoe (Apoe–/– mice) have high levels of cholesterol and spontaneously develop atherosclerotic lesions. Here, we treated Apoe–/– mice with apoE-encoding adenoviral vectors that induce plaque regression, and investigated whether macrophage removal from plaques during this regression resulted from quantitative alterations in the ability of monocytes to either enter or exit plaques. Within 2 days after apoE complementation, plasma cholesterol was normalized to wild-type levels, and HDL levels were increased 4-fold. Oil red O staining and quantitative mass spectroscopy revealed that esterified cholesterol content was markedly reduced. Plaque macrophage content decreased gradually and was 72% lower than baseline 4 weeks after apoE complementation. Importantly, this reduction in macrophages did not involve migratory egress from plaques or CCR7, a mediator of leukocyte emigration. Instead, marked suppression of monocyte recruitment coupled with a stable rate of apoptosis accounted for loss of plaque macrophages. These data suggest that therapies to inhibit monocyte recruitment to plaques may constitute a more viable strategy to reduce plaque macrophage burden than attempts to promote migratory egress.
- 14 May 2010
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 10 (6) , 453-460
Unravelling mononuclear phagocyte heterogeneity
Recent elegant studies in the mouse have increased our understanding of the origin and function of different macrophage and dendritic cell populations. However, these studies have also highlighted an old debate — how exactly should we classify the cells of the mononuclear phagocyte system? Here, five experts give their thoughts on this topic. When Ralph Steinman and Zanvil Cohn first described dendritic cells (DCs) in 1973 it took many years to convince the immunology community that these cells were truly distinct from macrophages. Almost four decades later, the DC is regarded as the key initiator of adaptive immune responses; however, distinguishing DCs from macrophages still leads to confusion and debate in the field. Here, Nature Reviews Immunology asks five experts to discuss the issue of heterogeneity in the mononuclear phagocyte system and to give their opinion on the importance of defining these cells for future research.
- 14 May 2010
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 10 (6) , 453-460
Unravelling mononuclear phagocyte heterogeneity
Recent elegant studies in the mouse have increased our understanding of the origin and function of different macrophage and dendritic cell populations. However, these studies have also highlighted an old debate — how exactly should we classify the cells of the mononuclear phagocyte system? Here, five experts give their thoughts on this topic. When Ralph Steinman and Zanvil Cohn first described dendritic cells (DCs) in 1973 it took many years to convince the immunology community that these cells were truly distinct from macrophages. Almost four decades later, the DC is regarded as the key initiator of adaptive immune responses; however, distinguishing DCs from macrophages still leads to confusion and debate in the field. Here, Nature Reviews Immunology asks five experts to discuss the issue of heterogeneity in the mononuclear phagocyte system and to give their opinion on the importance of defining these cells for future research.
- 5 February 2010
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 106 (2) , 227-229
Vascular Dendritic Cells as Gatekeepers of Lipid Accumulation Within Nascent Atherosclerotic Plaques
- 5 February 2010
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 106 (2) , 227-229
Vascular Dendritic Cells as Gatekeepers of Lipid Accumulation Within Nascent Atherosclerotic Plaques
- Open Access
- 21 January 2010
- Published by American Society of Hematology in Blood
- Vol. 115 (3) , e10-e19
Comparison of gene expression profiles between human and mouse monocyte subsets
Blood of both humans and mice contains 2 main monocyte subsets. Here, we investigated the extent of their similarity using a microarray approach. Approximately 270 genes in humans and 550 genes in mice were differentially expressed between subsets by 2-fold or more. More than 130 of these gene expression differences were conserved between mouse and human monocyte subsets. We confirmed numerous of these differences at the cell surface protein level. Despite overall conservation, some molecules were conversely expressed between the 2 species' subsets, including CD36, CD9, and TREM-1. Other differences included a prominent peroxisome proliferator-activated receptor γ (PPARγ) signature in mouse monocytes, which is absent in humans, and strikingly opposed patterns of receptors involved in uptake of apoptotic cells and other phagocytic cargo between human and mouse monocyte subsets. Thus, whereas human and mouse monocyte subsets are far more broadly conserved than currently recognized, important differences between the species deserve consideration when models of human disease are studied in mice.
- 21 January 2010
- Published by American Society of Hematology in Blood
- Vol. 115 (3) , e10-e19
Open AccessComparison of gene expression profiles between human and mouse monocyte subsets
Blood of both humans and mice contains 2 main monocyte subsets. Here, we investigated the extent of their similarity using a microarray approach. Approximately 270 genes in humans and 550 genes in mice were differentially expressed between subsets by 2-fold or more. More than 130 of these gene expression differences were conserved between mouse and human monocyte subsets. We confirmed numerous of these differences at the cell surface protein level. Despite overall conservation, some molecules were conversely expressed between the 2 species' subsets, including CD36, CD9, and TREM-1. Other differences included a prominent peroxisome proliferator-activated receptor γ (PPARγ) signature in mouse monocytes, which is absent in humans, and strikingly opposed patterns of receptors involved in uptake of apoptotic cells and other phagocytic cargo between human and mouse monocyte subsets. Thus, whereas human and mouse monocyte subsets are far more broadly conserved than currently recognized, important differences between the species deserve consideration when models of human disease are studied in mice.
- 1 October 2009
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 29 (10) , 1412-1418
Regulation of the Migration and Survival of Monocyte Subsets by Chemokine Receptors and Its Relevance to Atherosclerosis
Monocytes are central mediators in the advance of atherosclerotic plaque, making them a natural therapeutic target for reducing disease burden. Here, we highlight recent advances in our current understanding of monocyte heterogeneity and its relevance to regulation of monocyte accumulation and function within atherosclerotic plaques. Differences that distinguish monocyte subsets include differential expression of chemokine receptors, especially CCR2 and CX3CR1. Ablation of expression of these 2 receptors (or their ligands) in mice has an additive inhibition on monocyte recruitment to atherosclerotic plaques. Moreover, simultaneously interfering with 3 key pathways—CCR2, CX3CR1, and CCR5—essentially abolishes atherosclerosis in mice. Here, we discuss how these chemokine receptors act at multiple points on at least 1 monocyte subset, regulating their mobilization from bone marrow, survival, or recruitment to plaques. Finally, we discuss how this knowledge may be useful clinically, emphasizing that CX3CR1 may in particular be a viable target for therapeutic manipulation of monocyte-derived cell fate in cardiovascular disease.
- 1 October 2009
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 29 (10) , 1412-1418
Regulation of the Migration and Survival of Monocyte Subsets by Chemokine Receptors and Its Relevance to Atherosclerosis
Monocytes are central mediators in the advance of atherosclerotic plaque, making them a natural therapeutic target for reducing disease burden. Here, we highlight recent advances in our current understanding of monocyte heterogeneity and its relevance to regulation of monocyte accumulation and function within atherosclerotic plaques. Differences that distinguish monocyte subsets include differential expression of chemokine receptors, especially CCR2 and CX3CR1. Ablation of expression of these 2 receptors (or their ligands) in mice has an additive inhibition on monocyte recruitment to atherosclerotic plaques. Moreover, simultaneously interfering with 3 key pathways—CCR2, CX3CR1, and CCR5—essentially abolishes atherosclerosis in mice. Here, we discuss how these chemokine receptors act at multiple points on at least 1 monocyte subset, regulating their mobilization from bone marrow, survival, or recruitment to plaques. Finally, we discuss how this knowledge may be useful clinically, emphasizing that CX3CR1 may in particular be a viable target for therapeutic manipulation of monocyte-derived cell fate in cardiovascular disease.
- Open Access
- 13 July 2009
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 7, 28-30
The fate of monocytes in atherosclerosis
- 13 July 2009
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 7, 28-30
Open AccessThe fate of monocytes in atherosclerosis